BeOne's 2026 shareholder letter says the company's in-house development model has integrated AI and automation, and that BeOne is expanding the use of AI to optimize clinical trial design and accelerate recruitment. The same passage says the company has already shortened protocol-development time, sped proof-of-concept decisions and improved clinical-trial site monitoring.
Source
Company Archive pending